Lynne Ensor, Ph.D.

BACKGROUND

FOCUS AREAS

AWARDS & RECOGNITIONS

More than 28 years of experience in the life sciences industry, including over 2 decades at the FDA.

• Expert in Aseptic/Sterile Product Manufacturing for New, Generic, Biologic & Biosimiar Products
• Regulatory Product Quality Expectations (CDER Master Regulatory Reviewer)
• Regulatory Submissions (INDs, A/NDAs, BLAs, & DMFs)
• Pharmaceutical Microbiology
• Pharmacy Compounding
• Positron Emission Tomography
• cGxPs audits, Data Integrity, Risk Assessment
• Regulatory Biopharmaceutical Manufacturing Facility Compliance & Remediation
• Health Authority Facility Assessment/Inspection Tools, Support & Response
• Drug Shortage Prevention and Supply Chain Integrity
• Strategic Business Planning
• P& L management
• Marketing & Business Development
• Global Staff Management including Recruitment, Mentoring & Performance Evaluation
• Business Process Optimization
• Collaboration in Global, Cross- functional Environments

• United States Pharmacopeia: Outstanding Contribution to the Standards Award, 2025
• Parenteral Drug Association Service Award, 2016
• FDA Award for Excellence in Regulation (Initial Federal Regulation of Positron Emmission Tomography), 2012
• FDA: 4 Quality Step Increases & 57 agency awards (1999 – 2019)

As a Partner at ELIQUENT Life Sciences, Dr. Lynne Ensor provides strategic regulatory and compliance consulting to the pharmaceutical and biotechnology sectors. With 28 years of experience, she is a seasoned expert in sterile product manufacturing, regulatory affairs, compliance, and remediation. Prior to consulting since 2019, Dr. Ensor served for 21 years at the U.S. Food and Drug Administration (FDA) on CDER senior leadership teams (including the Office of Generic Drugs and Office of Pharmaceutical Quality), was a CDER Master Reviewer, was a member of the 2020-2025 U.S. Pharmacopeia’s Microbiology Expert Committee and earned a doctorate in Microbiology.

Dr. Lynne Ensor’s previous consulting experience includes having served a Senior Vice President and the Head of Global Compliance Consulting at Parexel International, as well as the Senior Global Managing Director for Pharma Biotech Consulting and Life Sciences Training at NSF International. While at the FDA, Dr. Ensor served in the Center for Drug Evaluation and Research (CDER) as the Deputy Office Director in the Office of Process and Facilities (OPF)/Office of Pharmaceutical Quality (OPQ), on the senior leadership teams in OPQ and Office of Generic Drugs (OGD), as the Director for OGD/Office of Pharmaceutical Science/OPF’s Divisions of Microbiology, and as a CDER Regulatory Master Reviewer. Lynne was a member of the 2020-2025 U.S. Pharmacopeia’s Microbiology Expert Committee. Her prior experience also includes Roche Biomedical Laboratories, script consulting for the Discovery Channel, and the University of Maryland’s School of Medicine. Lynne earned a B.S. in Biology and a Ph. D. in Microbiology from the University of Maryland.

Lynne has a record of leveraging scientific technology and regulatory insights to strategically develop and commercially manufacture safe and effective products of consistent quality which meet global regulatory expectations. Strong history of leveraging market knowledge and industry relationships to support patient availability to medical products. Data-driven with exceptional analytical skills and a foundational understanding of target global markets, customer needs, and life sciences business processes. Subject matter expert (SME) understanding of various global health authority regulations and guidance, such as FDA, MHRA, EMA, NMPA, PMDA, TGA, ANVISA, ICH, WHO, ISO, PIC/S and USP.

Ready for regulatory clarity? Contact Us.

(* Indicated fields are mandatory.)

By filling out this form and clicking submit, you agree to our Privacy Policy

By providing a telephone number and submitting this form, you are consenting to be contacted by SMS text message. Message & data rates may apply. You can reply STOP to opt-out of further messaging.

We do not share/sell personal data (phone numbers) and consent with third parties/affiliates or partners.